Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical is a company with a positive outlook as it has a disruptive technology in the medical device space with its fully disposable LIBERTY Endovascular Robotic Surgical System. Its lean and scalable business model, strong clinical validation, and global patent portfolio make it an attractive investment opportunity. With its recent successful commercial use at Emory Healthcare and additional patents granted globally, the company is poised to lead the next wave of innovation in robotic-assisted vascular care.

Bears say

Microbot Medical is a medical device company with a limited market release of their robotic endovascular system targeting peripheral vascular procedures. While the company has the potential for a multi-billion dollar opportunity, their limited market release and small sales and marketing team may result in slower than anticipated commercial uptake. Additionally, the company faces forecasting and competitive risks in the highly competitive global market for medical devices.

Microbot Medical (MBOT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.